Incyte (INCY) announced the Japan Ministry of Health, Labour and Welfare approval of Zynyz in combination with carboplatin and paclitaxel for the first-line treatment of advanced squamous cell carcinoma of the anal canal. “Today’s approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC,” said Yasuyuki Ishida, general manager, Incyte Biosciences Japan G.K. “By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte Steps Into Late-Stage Colorectal Cancer Race With New Phase 3 Trial of INCA33890
- Incyte announces European Commission approval of second indication for Minjuvi
- Incyte’s mCALR Monoclonal Antibody Shows Promise Amid Complex Myelofibrosis and Thrombocythemia Treatment Landscape
- Incyte’s Latest Study Completion: A Step Forward in Drug Interaction Insights
- Incyte Board Member Hervé Hoppenot Retires